Eggs are one of the most remarkable functional ingredients in food manufacturing. They are versatile, high-performing, and deeply embedded in thousands of formulations worldwide. They’re also one of the most fragile foundations on which to build a global supply chain. That tension is exactly where The Bland Company lives, and today I’m excited to announce that we led their pre-seed round.

A PROTEIN PLATFORM, NOT JUST AN INGREDIENT COMPANY

The Bland Company is a protein functionalization platform that uses a proprietary biochemical process that takes abundant, undervalued agricultural side streams and transforms them into high-performance functional proteins engineered for specific industrial applications. 

The global food manufacturing supply chain depends on a surprisingly narrow set of commodity animal proteins to deliver the functional properties like solubility, emulsification, foaming, gelling, and binding that make processed food work at scale. These proteins are the invisible architecture behind everything from baked goods to sauces to snack bars to nutritional beverages, across every major food market in the world. And the supply chains that deliver them are volatile, concentrated, and increasingly fragile.

What The Bland Company has built is a platform that can produce an expanding library of functional protein ingredients, each tuned for different performance characteristics and applications. The process is feedstock-agnostic, adapting across multiple agricultural inputs available in different regions globally. It’s capital-light by design – no fermentation, no bioreactors, no novel equipment, and plugs into existing food production infrastructure. 

This means manufacturers can adopt these ingredients without overhauling their lines: The Bland Company’s B2B ingredient platform is designed to slot directly into the procurement workflows of the world’s largest food manufacturers, built as a global business from the outset.

WHERE BIO MEETS AI

Protein science is entering a new era, and AI is accelerating the timeline dramatically.

The last wave of alternative protein companies largely relied on brute-force screening and traditional food science to find workable formulations. It was slow, expensive, and often resulted in products that were “good enough” but never truly competitive with animal-derived ingredients. 

What’s changed is that computational tools, protein structure prediction, molecular simulation, and machine learning-guided process optimization are making it possible to understand and engineer protein functionality at a level of precision that wasn’t available even a few years ago.

The Bland Company sits at this intersection. Their platform solves a fundamental protein engineering problem: understanding how different feedstocks respond to their biochemical process, predicting which substrates will yield which functional properties, and optimizing processing parameters to hit specific performance targets. 

As AI-driven tools for protein modeling and bioprocess optimization continue to mature, platforms like The Bland Company’s become exponentially more powerful. The feedback loop between experimentation and computational prediction gets tighter, the R&D cycle accelerates, and the product library expands faster.

The companies that will define the next decade of food, materials, and industrial biology are the ones building programmable platforms where the intersection of wet-lab science and computational intelligence creates compounding advantages over time. Bland’s protein functionalization platform is exactly this kind of company. 

WHY START WITH EGGS

Eggs are one of the single largest functional ingredients in global food manufacturing. One-third of all egg production goes not to consumers, but to industrial applications. These egg proteins serve as the workhorse behind texture, structure, and stability in thousands of formulations. From a functional perspective, eggs are one of the most versatile ingredients in a formulator’s toolkit, which is precisely why they’ve been so hard to replace.

But that centrality has created enormous exposure. Avian flu outbreaks, cage-free regulation transitions, climate volatility, and feed cost swings have caused egg prices to fluctuate by 2–3x over the past 18 months. For manufacturers running global supply chains on thin margins, this is a structural vulnerability. And despite decades of attempts, no one has built an alternative that delivers both functional parity and cost efficiency at scale.

Eggs represent the ideal beachhead for a platform like Bland’s: the largest addressable use case, with acute and worsening customer pain, and no adequate existing solution. Starting here lets the team prove their technology against the most commercially valuable problem first and then expand from a position of strength. Early results are compelling, with Bland’s first-generation ingredients already showing strong solubility, foaming, and emulsification concurrently in some benchmarks surpassing egg-white performance.

THE PLATFORM EXPANDS FROM HERE

The same core process can be tuned to produce functional ingredients across entirely different categories. Each new feedstock responds differently, with different functionality amplified depending on the substrate’s composition and the parameters applied. That variability is the foundation of an expanding product library.

The long-term model is a biorefinery: one plant feedstock in, multiple high-performance functional ingredients out, serving food and potentially non-food applications. No large ingredient business is built on a single product, and Bland’s architecture is designed from the ground up for that kind of expansion. Whoever builds reliable, cost-competitive functional proteins from plant-based inputs doesn’t just win a category, they become essential infrastructure for modern food manufacturing globally.

THE TEAM

Cofounders Yash Khandelwal and Micol Hafez are both trained biochemists with deep experience in protein science and food formulation. What sets them apart is the combination of scientific rigor with a relentless focus on commercial viability. They’ve built their cost model from first principles, targeting economics that don’t just compete with commodity proteins, they undercut them. They’ve designed their process around unit operations that already exist at protein production plants. And they’ve been disciplined about starting with the largest, most commercially urgent problem rather than chasing the most technically interesting one. 

That kind of strategic clarity at the pre-seed stage is rare, and it’s a big part of why we led this round.

WHY THIS MATTERS NOW

The convergence is happening. AI is transforming how we understand and design proteins. Global food manufacturers are actively seeking supply chain resilience. And advances in protein restructuring science have reached a point where chemical methods can deliver functional performance that was previously only achievable through expensive biological processes. 

At Initialized, the investments I have the deepest conviction in are the ones building net new capability. Companies that expand what’s possible rather than incrementally improving what already exists. Bland is building something that doesn’t exist today: a flexible, capital-efficient, globally scalable platform for producing high-performance functional proteins from abundant agricultural inputs, at price points the food industry can actually adopt.

I couldn’t be more excited to partner with Yash and Micol as they build this out. If you’re a food company looking for high-performance, cost-stable protein ingredients or a scientist who wants to work at the frontier of protein chemistry and AI-driven bioprocess design, reach out to the team.